Genetic testing firm 23andMe declares chapter

On Sunday, the genetic testing and heritage firm 23andMe introduced that it had entered Chapter 11 chapter and was asking a court docket to rearrange its sale. The corporate has been dropping cash for years, and a battle between its board and CEO about future instructions led to your entire board resigning again in September. Mentioned CEO, Anne Wojcicki, has now resigned and might be pursuing an try and buy the corporate and take it personal.

At stake is the destiny of genetic information from the corporate’s 15 million prospects. The corporate has secured sufficient funding to proceed operations whereas a purchaser is discovered, and although US legislation limits how genetic information can be utilized, the pending sale has raised important privateness issues.

Dangerous enterprise

The corporate launched across the time that “gene chips” first allowed folks to broadly scan the human genome for websites the place variations had been frequent. Just a few of those variants are related to illnesses, and 23andMe acquired approval to check for quite a lot of these. However its large promoting level for many individuals was the chance to discover their heritage. This relied on wanting broadly on the patterns of variation and evaluating these to the patterns sometimes discovered in numerous geographic areas. It’s an imperfect evaluation, however it will possibly typically present an honest big-picture decision of an individual’s ancestry.

23andMe confronted quite a lot of challenges, although. For starters, the gene chips shortly grew to become commodities, permitting a wide range of rivals to enter the sphere, a few of which had stronger backgrounds in issues like linking genealogies to public information. This commodification additionally meant that many potential 23andMe companions within the pharmaceutical business, who could be considering gene/illness linkages, might affordably construct their very own databases or just depend on a number of the public assets which have since been developed, just like the UK’s Biobank.